Danaher to acquire Aldevron in deal valued at $9.6B
Danaher announced it has signed a deal to buy DNA and messenger RNA manufacturer Aldevron for approximately $9.6 billion. Aldevron will operate as a standalone company in Danaher's Life Sciences business segment and is expected to boost Danaher's activities in genomic medicine. Read More
Conferences
Science Briefs
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
